Cytek Biosciences, Inc.
CTKBHealthcareNASDAQMedical Devices
Scan Results
Daily timeframeCytek Biosciences, Inc., a cell analysis solutions company, provides cell analysis tools that facilitate scientific advances in biomedical research and clinical applications. Valued at $726.6M, CTKB is a small-cap name in its sector. The company offers Cytek aurora, northern lights systems, and Cytek aurora evo systems delivers cell analysis; Cytek Aurora CS System, a cellular complexity to perform additional downstream genomic and proteomic studies using phenotyping approaches; enhanced small particle detection; Cytek amnis imagestream imaging flow cytometers; Cytek guava muse cell analyzers; Cytek muse micro cell analyzers; Cytek guava easyCyte flow cytometers; and Cytek orion reagent cocktail preparation systems.
Market Cap
$726.6M
Beta
1.16
P/E (TTM)
—
P/E (Fwd)
79.86
EPS (TTM)
$-0.62
EPS (Fwd)
$0.07
ROE
-23.0%
ROA
-6.3%
Cash
$262.0M
Total Debt
$26.5M
Free CF
$9.3M
52W Change
34.7%
Annual Financials
Cash vs Debt
Where CTKB stands vs its 150-day and 200-day moving averages
As of the October 12, 2026 close, CTKB finished 19.60% above its 150-day moving average ($4.54) and 17.28% above its 200-day moving average ($4.63). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is CTKB overbought or oversold?
At the October 12, 2026 close, CTKB's RSI(14) was 53.5, in neutral territory (between 30 and 70). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
Cytek Biosciences, Inc. holds $262.0M in cash against $26.5M in total debt, giving it a net cash position. This means the company could theoretically pay off all its debt and still have cash remaining. The company generates $9.3M in free cash flow annually, which funds everything from R&D to shareholder returns without needing external financing. Return on equity stands at -23.0%, which is negative for the sector. ROE measures how effectively a company uses shareholder capital to generate profits. Revenue has grown from $164.0M (2022) to $201.5M (2025), reflecting a 23% increase over the period.
The strong cash position relative to debt provides a financial cushion that reduces balance sheet risk. It is important to consider these factors alongside broader market conditions and individual financial goals when reviewing CTKB.